Merck Announces Second-Quarter 2014 Financial Results
Second-Quarter 2014 Non-GAAP EPS of $0.85, Excluding Certain Items, and GAAP EPS of $0.68 2014 Full-Year Non-GAAP EPS Target of $3.43 to $3.53, Excluding Potential Venezuelan Bolivar Devaluation and Certain Other Items; 2014 Full-Year GAAP EPS Target of $4.44 to $4.77 2014 Full-Year Non-GAAP EPS Target Includes $0.06 to $0.09 Anticipated Dilution From Planned Sale of Merck Consumer Care and Research Collaboration With Bayer, and Planned Acquisition of Idenix Generated Worldwide Sales of $10.9 Billion, a Decrease of 1 Percent, Reflecting Unfavorable Impact of Patent Expiries, Divested Products and Decline in Sales of Hepatitis C Products Grew Top Five Franchises by 6 Percent in Total Pembrolizumab (MK-3475), an Investigational Anti-PD-1 Antibody, Accepted in Second Quarter for Regulatory Review in Both the United States and European Union Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced financial results for the second quarter of 2014. Second Quarter
https://www.merck.com/news/merck-announces-second-quarter-2014-financial-results/
Merck Announces First-Quarter 2014 Financial Results
First-Quarter 2014 Non-GAAP EPS of $0.88, Excluding Certain Items; GAAP EPS of $0.57; Confirms 2014 Full-Year Non-GAAP EPS Target of $3.35 to $3.53, Excluding Certain Items; GAAP EPS Range of $2.15 to $2.47 Worldwide Sales were $10.3 Billion, a Decrease of 4 Percent, Reflecting Unfavorable Impact of Patent Expiries and a 2 Percent Unfavorable Impact from Foreign Exchange Strategic Initiatives Drove Cost Reductions and Portfolio Divestitures, Generating First-Quarter 2014 Benefits Sales of REMICADE, SIMPONI and ISENTRESS, as well as Diabetes and Vaccines Franchises Grew FDA Approved GRASTEK and RAGWITEK Sublingual Allergen Extract Immunotherapy Tablets and Accepted Filings for V503 and Suvorexant; Company Announced Progress in Key Clinical Programs Including HCV and HIV Repurchased $7.5 Billion of Common Stock Over Previous 12 Months as Part of Ongoing Share Repurchase Program Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced financial results for the
https://www.merck.com/news/merck-announces-first-quarter-2014-financial-results/
Merck Announces Fourth-Quarter and Full-Year 2013 Financial Results
Fourth-Quarter 2013 Non-GAAP EPS Increased by 6 Percent Over Prior Year to $0.88, Excluding Certain Items; GAAP EPS Decreased by 13 Percent to $0.26. Full-Year 2013 Non-GAAP EPS of $3.49, Excluding Certain Items; GAAP EPS of $1.47. Fourth-Quarter 2013 Worldwide Sales Were $11.3 Billion, a Decrease of 4 Percent Reflecting Unfavorable Impact of Patent Expiries and a 3 Percent Negative Impact from Foreign Exchange. Full-Year 2013 Worldwide Sales Were $44.0 Billion, a Decrease of 7 Percent Reflecting Unfavorable Impact of Patent Expiries and a 2 Percent Negative Impact from Foreign Exchange. Strong Full-Year Sales Growth for GARDASIL, REMICADE, SIMPONI, ISENTRESS, ZOSTAVAX and the Diabetes Franchise. Returned $11 Billion to Shareholders in 2013 Through Dividends and Share Repurchases. Accelerated Development Program for MK-3475, Including Announcement of Four Collaborations to Evaluate Novel Combination Regimens, Initiation of a Phase I Study in 20 New Cancer Types and Rolling Submission
https://www.merck.com/news/merck-announces-fourth-quarter-and-full-year-2013-financial-results/
Merck Announces Third-Quarter 2013 Financial Results
2013 Third-Quarter Non-GAAP EPS of $0.92, Excluding Certain Items; GAAP EPS of $0.38 Worldwide Sales were $11.0 Billion, a Decrease of 4 Percent Reflecting the Unfavorable Impact of Patent Expiries and a 2 Percent Negative Impact from Foreign Exchange Strong Growth in Vaccines and Immunology as well as ISENTRESS ‘Breakthrough Therapy’ Designation Granted for MK-5172/MK-8742, in Development for the Treatment of Chronic Hepatitis C Virus Infection; V503, Merck’s Investigational 9-valent HPV Vaccine has Completed Pivotal Phase III Study, on Track for 2013 Submission Narrows Full-Year Non-GAAP EPS Target to $3.48 to $3.52; GAAP EPS Target to $1.61 to $1.79 Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced financial results for the third quarter of 2013. $ in millions, except EPS amounts Third Quarter 2013 Third <br />Quarter <br />2012 Sales $11,032 $11,488 GAAP EPS 0.38 0.56 Non-GAAP EPS that excludes items listed below1 0.92 0.95 GAAP Net
https://www.merck.com/news/merck-announces-third-quarter-2013-financial-results/
Merck Announces Second-Quarter 2013 Financial Results
2013 Second-Quarter Non-GAAP EPS of $0.84, Excluding Certain Items; GAAP EPS of $0.30 Worldwide Sales were $11.0 Billion, a Decrease of 11 Percent Reflecting the Unfavorable Impact of Patent Expiries and a 3 Percent Negative Impact from Foreign Exchange Partially Offset by Global Performance of Human Health Products Growth in Key Franchises Including Vaccines, Diabetes and Immunology Continued Return of Cash to Shareholders, Including $5 Billion Accelerated Share Repurchase Announced in May Reaffirmed Full-Year Non-GAAP EPS Target of $3.45 to $3.55, Excluding Certain Items; Revised GAAP EPS Range to $1.84 to $2.05 Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced financial results for the second quarter of 2013. $ in millions, except EPS amounts Second Quarter 2013 Second Quarter 2012 Sales $11,010 $12,311 GAAP EPS 0.30 0.58 Non-GAAP EPS that excludes items listed below1 0.84 1.05 GAAP Net Income2 906 1,793 Non-GAAP Net Income
https://www.merck.com/news/merck-announces-second-quarter-2013-financial-results/
Merck Announces First-Quarter 2013 Financial Results
2013 First-Quarter Non-GAAP EPS of $0.85, Excluding Certain Items; GAAP EPS of $0.52 Worldwide Sales were $10.7 Billion, a Decrease of 9 Percent Primarily as a Result of Patent Expiries, and Including a 2 Percent Unfavorable Impact from Foreign Exchange Growth in Vaccines, Immunology, HIV, Animal Health and Consumer Care Products Received Breakthrough Therapy Designation for Lambrolizumab, an Investigational Candidate for Advanced Melanoma; Five Products Currently Under Regulatory Review Announced New $15 Billion Share Repurchase Program; Plans to Repurchase Approximately $7.5 Billion of Common Stock over the Next Twelve Months Revises 2013 Full-Year Non-GAAP EPS Target to $3.45 to $3.55, Excluding Certain Items; Revises GAAP EPS Range to $1.92 to $2.16 Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced financial results for the first quarter of 2013. $ in millions, except EPS amounts First Quarter 2013 First <br />Quarter <br />2012 Sales
https://www.merck.com/news/merck-announces-first-quarter-2013-financial-results/
Merck Announces Full-Year and Fourth-Quarter 2012 Financial Results
2012 Full-Year Non-GAAP EPS of $3.82, Excluding Certain Items; GAAP EPS of $2.16; Fourth-Quarter Non-GAAP EPS of $0.83, Excluding Certain Items; GAAP EPS of $0.46 2012 Full-Year Worldwide Sales Were $47.3 Billion, a Decrease of 2 Percent, Including a 3 Percent Unfavorable Impact from Foreign Exchange; Fourth-Quarter Worldwide Sales Were $11.7 Billion, a Decline of 5 Percent, Including a 2 Percent Unfavorable Impact from Foreign Exchange Full-Year and Fourth-Quarter Double-Digit Global Sales Growth for JANUVIA, JANUMET, GARDASIL, VICTRELIS and ZOSTAVAX Offset the Decline in SINGULAIR Sales Following Patent Expiry in the United States Provides Update on Odanacatib Program; Now Anticipates Filing in 2014 2013 Full-Year Non-GAAP EPS Target of $3.60 to $3.70, Excluding Certain Items; GAAP EPS Range of $2.03 to $2.26 Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced financial results for the fourth quarter and full year of 2012. $ in millions, except EPS
https://www.merck.com/news/merck-announces-full-year-and-fourth-quarter-2012-financial-results/
Merck Announces Third-Quarter 2012 Financial Results
2012 Third-Quarter Non-GAAP EPS Increased to $0.95, Excluding Certain Items; GAAP EPS of $0.56 Worldwide Sales of $11.5 Billion, a Decrease of 4 Percent; Comparable to Third-Quarter 2011 Sales, Excluding the Unfavorable Impact of Foreign Exchange Double-Digit Global Sales Growth for JANUVIA, JANUMET, GARDASIL, VICTRELIS, ZOSTAVAX and ISENTRESS; Offset by the Decline in SINGULAIR Sales Following Patent Expiry in the United States Anticipates Multiple New Product Submissions in 2012-2013, Including Suvorexant and Odanacatib Narrows 2012 Full-Year Non-GAAP EPS Target to $3.78 to $3.82, Excluding Certain Items; GAAP EPS Range of $2.08 to $2.24 Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced financial results for the third quarter of 2012. $ in millions, except EPS amounts Third Quarter 2012 Third Quarter 2011 Sales $11,488 $12,022 GAAP EPS 0.56 0.55 Non-GAAP EPS that excludes items listed below1 0.95 0.94 GAAP Net Income2 1,729
https://www.merck.com/news/merck-announces-third-quarter-2012-financial-results/
Merck Announces Second-Quarter 2012 Financial Results
2012 Second-Quarter Non-GAAP EPS Increased 11 Percent Over Prior Year to $1.05, Excluding Certain Items; GAAP EPS of $0.58 Worldwide Sales Up One Percent to $12.3 Billion, Five Percent Excluding Foreign Exchange; Pharmaceuticals, Animal Health and Consumer Care All Contributed to Growth Double-Digit Global Growth for JANUVIA, JANUMET, VICTRELIS, ISENTRESS, GARDASIL and ZOSTAVAX On Track for Six Major Filings in 2012-2013, Including Suvorexant and Odanacatib Reaffirmed 2012 Full-Year Non-GAAP EPS Target of $3.75 to $3.85, Excluding Certain Items; GAAP EPS Range of $2.04 to $2.30 Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced financial results for the second quarter of 2012. $ in millions, except EPS amounts Second Quarter 2012 Second <br />Quarter <br />2011 Sales $12,311 $12,151 GAAP EPS 0.58 0.65 Non-GAAP EPS that excludes items listed below 1 1.05 0.95 GAAP Net Income2 1,793 2,024 Non-GAAP Net Income that excludes items listed below 1,2
https://www.merck.com/news/merck-announces-second-quarter-2012-financial-results/
Merck Announces First-Quarter 2012 Financial Results
2012 First-Quarter Non-GAAP EPS Increased Eight Percent Over Prior Year to $0.99, Excluding Certain Items; GAAP EPS of $0.56 Worldwide Sales Grew One Percent to $11.7 Billion Driven by Growth of Three Percent in Pharmaceuticals (Six Percent, Excluding the Impact of the J&J Arbitration Settlement), Eight Percent in Animal Health and Seven Percent in Consumer Care Strong Growth Across All Major Businesses Partially Offset by Reductions in Alliance Revenue and Third-Party Manufacturing Sales Double-Digit Global Growth for JANUVIA, JANUMET, GARDASIL, ISENTRESS and Strong Performance for VICTRELIS Reaffirmed 2012 Full-Year Non-GAAP EPS Target of $3.75 to $3.85, Excluding Certain Items; GAAP EPS Range of $2.04 to $2.30 Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced financial results for the first quarter of 2012. $ in millions, except EPS amounts First Quarter 2012 First Quarter 2011 Sales $11,731 $11,580 GAAP EPS 0.56 0.34 Non-GAAP EPS
https://www.merck.com/news/merck-announces-first-quarter-2012-financial-results/